Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Show more
Location: 9237 East Via de Ventura Boulevard, Scottsdale, AZ, 85258, United States | Website: https://journeymedicalcorp.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
183.3M
52 Wk Range
$3.54 - $8.25
Previous Close
$7.87
Open
$7.72
Volume
995,780
Day Range
$7.72 - $8.90
Enterprise Value
187.4M
Cash
21.07M
Avg Qtr Burn
-1.735M
Insider Ownership
31.64%
Institutional Own.
29.12%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Emrosi™ (Formerly DFD-29) Details Papulopustular rosacea | Approved Quarterly sales |